IMS Health — Merger or Acquisition (July 2016)
23 slides from IMS Health's merger presentation, Jul 19, 2016
Slide 1: Quintiles and IMS Health Alliance - Rule 425 filing legend
Confidential - Quintiles and IMS Health Alliance Filed by Quintiles Transnational Holdings Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: IMS Health Holdings, Inc. Commi
Slide 2: Enriched Studies: Quintiles-IMS Health Real-World Evidence Alliance
Enriched Studies Quintiles-IMS Health Real-World Evidence Alliance
Slide 3: Quintiles and IMS Health Alliance
Confidential - Quintiles and IMS Health Alliance
Slide 4: Quintiles and IMS Health Alliance
Confidential - Quintiles and IMS Health Alliance
Slide 5: Quintiles and IMS Health Alliance
Confidential - Quintiles and IMS Health Alliance
Slide 6: Quintiles and IMS Health Alliance
Confidential - Quintiles and IMS Health Alliance
Slide 7: Note on IMS Health-Quintiles Pending Transaction
Note on IMS Health-Quintiles Pending Transaction IMS Health and Quintiles announced a transaction on May 3, 2016 This transaction is very exciting. But it is subject to certain regulatory approvals, shareholder approvals and customary closing conditions. It is expected to close in the second half of
Slide 8: Traditional trade-offs of observational studies
Traditional trade-offs of observational studies Retrospective analysis Prospective data collection Pros Large data sets Real-life patterns Analysis can uncover new insights Control around collected data, confounders, sample size Focus on hypothesis Cons Data verification/ quality issues Incomplete d
Slide 9: The real-world landscape is changing
The real-world landscape is changing Challenges facing real-world evidence generation Sponsors need to generate better data, reduce inefficiencies and maximize value Regulatory needs: Regulatory requirements and conditional reimbursement Electronic health data: Increased availability and opportuniti
Slide 10: The solution: Enriched Studies
The solution: Enriched Studies Use retrospective analysis to characterize patient populations, assess feasibility for the study Generate insights from rich RWD about treatments and patients Use learnings to design practical, optimal prospective study Target appropriate sites for prospective study Co
Slide 11: How Enriched Studies work in practice
How Enriched Studies work in practice Retrospective Analyze RWD to form the foundation of the analysis “Bridge” Use retro learnings to make a better prospective study Prospective Collect and analyze new data Identify data sources Extract needed data Create database for analysis Analyze to establish
Slide 12: Integrated multi-source data for a comprehensive patient view
Integrated multi-source data for a comprehensive patient view EMR data Other datasets (e.g. claims) Study database EMR “backbone” Aids patient recruitment Provides core patient information Retrospective Prospective study EMR data Other datasets (e.g. claims) Data collected directly from MD (e-CRF) P
Slide 13: Quintiles-IMS Health collaboration: key study steps
Quintiles-IMS Health collaboration Key study steps Objective Finalize protocol and study planning by using secondary data integrated with site expertise Reduce timelines with patient targeting and optimize eCRF design to reduce the site burden Provide fit-for-research integrated data sources with on
Slide 14: Applying enriched RWD studies
Applying enriched RWD studies Initial perspectives on applications – for discussion: Strong foundational data, where most of the data is complete but key variables are not collected electronically; can enrich for the last 10-20% of data, rather than gathering all the data through eCRF TAs where the
Slide 15: Achieve better patient outcomes with an innovative approach
Achieve better patient outcomes with an innovative approach
Slide 16: Appendix
Appendix QO QuintTILes’ imshealtty
Slide 17: Alliance capabilities: Synergies provide the best solutions
Alliance capabilities: Synergies provide the best solutions Project Management Unified global coordination and project management; single contact point for project management and contracting Early collaboration on the research design & data collection approach Full scale of analytic methods and data
Slide 18: Study Applications for Quintiles-IMS Health Alliance
Study Applications for Quintiles-IMS Health Alliance A tailored approach to evidence planning and generation, combining best in class evidence generation approaches allowing clients to use and re-use information efficiently and consistently across multiple departments (Medical Affairs, Clinical Deve
Slide 19: Our Solutions: Drug Utilization Studies (DUS)
Our Solutions: Drug Utilization Studies (DUS) Innovative benefit risk programs including full spectrum primary and secondary data, PASS study design and execution for monitoring and measuring safety and effectiveness to meet regulatory requirements and your stakeholder objectives Efficiencies levera
Slide 20: Our Solutions: Enriched RWD Studies
Our Solutions: Enriched RWD Studies Enhanced value of study insights Optimize collection of data needed to address critical questions by leveraging existing secondary data from health IT systems, supplemented by prospective collection Faster access to insights from secondary data enabling early publ
Slide 21: Our Solutions: Real World Evidence Hubs
Our Solutions: Real World Evidence Hubs Multi-asset and geo-scalable evidence platform leveraging secondary electronic data with supporting analytic tools, providing integrated view of outcomes and treatments Addresses gaps in analytic information, speed of evidence generation & response Efficiency
Slide 22: The benefits
Timelines Streamline study execution & patient recruitment through improved physician and patient targeting, protocol feasibility and optimization Patient-centricity Enrich existing data with patient-reported data and database driven and site based feasibility Participation Improve site and patient
Slide 23: Case study: Enriched RWD Epidemiology Study
Case study: Enriched RWD Epidemiology Study Delivered through IMS and Quintiles Collaboration Primary objective: describe disease management patterns and clinical evolution over 3 years in type 2 diabetes patients initiating a 2nd line anti-diabetic treatment Scope: 30+ countries Required expertise:
IMS Health Holdings — Merger or Acquisition (July 2016) on 6ix